LACTOBACILLUS REUTERI AGAINST HELICOBACTER PYLORI: IN VITRO AND IN VIVO EFFICACY

DOI: https://doi.org/10.29296/25877305-2019-12-10
Download full text PDF
Issue: 
12
Year: 
2019

Professor Yu. Uspensky(1, 2), MD; N. Baryshnikova(2), 3, Candidate of Medical Sciences 1-Saint Petersburg State Pediatric Medical University 2-Acad. I.P. Pavlov First Saint Petersburg State Medical University 3-Institute of Experimental Medicine, Saint Petersburg

The paper discusses the evolution of eradication therapy. It emphasizes the efficacy and safety of Helinorm used alone and in combination with standard eradication therapy.
Keywords: 
gastroenterology
eradication therapy
Helinorm

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Blaser M. Hypothesis: changing relationships of Helicobacter pylori and humans: implications for health and disease // J. Infect. Dis. – 1999; 179 (6): 1523–30.
  2. Cohen H., Gramisu M., Fitzgibbons P. et al. Campylobacter pylori: associations with antral and fundal mucosal histology // Am. J. Gastroenterol. – 1989; 84: 367–71.
  3. Hocker M., Hohenberger P. Helicobacter pylori virulence factors – one part of a big picture // Lancet. – 2003; 362 (9391): 1231–3.
  4. Malfertheiner P., Mégraud F., O’Morain C. Guidelines for the Management of Helicobacter Pylori Infection (2005). URL: https://061fb23c-fc26-4745-b739-1ba460436926.filesusr.com/ugd/d8d367_0d02c9a8554c476995c8bd67e47d0eca.pdf (data obraschenija 06.12.2019).
  5. Stolte M., Eidit S., Ritter M. et al. Campylobacter pylori and gastritis // Pathologe. – 1989; 10: 21–6.
  6. Uspenskiy Y., Baryshnikova N., Smirnova A. et al. Prevalence of Helicobacter pylori infection in healthy volunteers and duodenal ulcer patients in St.-Petersburg, Russia // J. Gastroenterol. Hepatol. – 2010; 25 (Suppl. 3): A43.
  7. Warren J., Marshall B. Unindentified curved bacilli on gastric epithelium in chronic gastritis // Lancet. – 1983; 1 (8336): 1273–5.
  8. Marshall B., Armstrong J., McGechie D. et al. Attempt to fulfil Koch’s postulates for pyloric Campylobacter // Med. J. Australia. – 1985; 142 (8): 436–9.
  9. Marshall B., Armstrong J., Francis G. et al Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis // Digestion. – 1987; 37 (suppl. 2): 16–30.
  10. Marshall B., McGechie D., Rogers P. et al. Pyloric Campylobacter infection and gastroduodenal disease // Med. J. Australia. – 1985; 142 (8): 439–44.
  11. Ciccaglione A., Cellini L., Grossi L. et al. A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study // Helicobacter. – 2015. DOI: 10.1111/hel.12209.
  12. George L., Borody T., Andrews P. et al. Cure of duodenal ulcer after eradication of Helicobacter pylori // Med J Aust. – 1990; 153 (3): 145–9.
  13. Iser J., Buttigieg R., Iseli A. Low dose, short duration therapy for the eradication of Helicobacter pylori in patients with duodenal ulcer // Med. J. Aust. – 1994; 160 (4): 192–6.
  14. Wagner S., Varrentrapp M., Haruma K. et al. The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection // Z. Gastroenterol. – 1991; 29 (11): 595–8.
  15. Bazzoli F., Pozzato P. Therapy of H. pylori infection // J. Physiol. Pharmacol. – 1997; 48 (Suppl. 4): 39–46.
  16. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group // Gut. – 1997; 41: 8–13.
  17. Malfertheiner P., Mégraud F., O’Morain C. et al. Current concepts in the management of Helicobacter pylori infection – the Maastricht 2-2000 Consensus Report // Aliment. Pharmacol. Ther. – 2002; 16: 167–180.
  18. Malfertheiner P., Megraud F., O’Morain C. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report // Gut. – 2007; 56: 772–81. DOI: 10.1136/gut.2006.101634.
  19. Malfertheiner P. et al. Management of Helicobacter pylori infection: the Maastricht IV/ Florence Consensus Report // Gut. – 2012; 61: 646–64.
  20. Malfertheiner P., Megraud F., O’Morain C. et al. On behalf of the European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report // Gut. – 2017; 66: 6–30. DOI: 10.1136/gutjnl-2016-312288.
  21. Uspenskij Ju.P., Suvorov A.N., Baryshnikova N.V. Infektsija Helicobacter pylori v klinicheskoj praktike / SPb: InformMed, 2011; s. 497–537 [Uspenskii Yu.P., Suvorov A.N., Baryshnikova N.V. Infektsiya Helicobacter pylori v klinicheskoi praktike / SPb: InformMed, 2011; s. 497–537 (in Russ.)].
  22. Uspenskij Ju.P., Suvorov A.N., Baryshnikova N.V. Infektsija Helicobacter pylori v klinicheskoj praktike / SPb, InformMed, 2011; 497–506 [Uspenskii Yu.P., Suvorov A.N., Baryshnikova N.V. Infektsiya Helicobacter pylori v klinicheskoi praktike / SPb, InformMed, 2011; 497–506 (in Russ.)].
  23. Szajewska H.. Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment // Aliment. Pharmacol. Ther – 2010; 32: 1069–79.
  24. Molina-Infante J., Gisbert J. Probiotics for Helicobacter pylori eradication therapy: not ready for prime time // Rev. Esp. Enferm. Dig. – 2013; 105 (8): 441–4.
  25. Tong J., Ran Z., Shen J. et al. Meta-analysis: The effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy // Aliment. Pharmacol. Ther. – 2007; 25: 155–68.
  26. Wang Z., Gao Q., Fang J. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy // J. Clin. Gastroenterol. – 2013; 47: 25–32.
  27. Sachdeva A., Nagpal J. Meta-analysis: Efficacy of bovine lactoferrin in Helicobacter pylori eradication // Aliment. Pharmacol. Ther. – 2009; 29: 720–30.
  28. Zou J., Dong J., Yu X. Meta-analysis: The effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy // Helicobacter. – 2009; 14: 119–27.
  29. Sachdeva A., Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: A systematic review and meta-analysis of randomized-controlled trials // Eur. J. Gastroenterol. Hepatol. – 2009; 21: 45–53.
  30. Dinleyici E., Kara A., Ozen M. et al. Saccharomyces boulardii CNCM I-745 in different clinical conditions // Expert Opin. Biol. Ther. – 2014; 14: 1593–609.
  31. Kozlova D.I. Sostojanie kishechnogo mikrobiotsenoza i techenie H. pylori-assotsiirovannogo gastrita v uslovijah eradikatsionnoj i sinbioticheskoj terapii. Avtoref. diss. … kand. med. nauk. SPb, 2004; 21 s. [Kozlova D.I. Sostoyanie kishechnogo mikrobiotsenoza i techenie H. pylori-assotsiirovannogo gastrita v usloviyakh eradikatsionnoi i sinbioticheskoi terapii. Avtoref. diss. … kand. med. nauk. SPb, 2004; 21 s. (in Russ.)].
  32. Canducci F., Cremonini F., Armuzzi A. et al. Probiotics and Helicobacter pylori eradication. // Dig. Liver Dis.: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. – 2002; 34 (suppl. 2): 81–3.
  33. Suvorov A.N., Baryshnikova N.V., Svarval' A.V. i dr. Vozmozhnosti nekotoryh probioticheskih shtammov ve radikatsii Helicobacter pylori in vitro i in vivo // Farmateka. – 2018; 2 (355): 74–8 [Suvorov A.N., Baryshnikova N.V., Svarval A.V. et al. Possibilities of some probiotic strains in the eradication of Helicobacter pylori in vitro and in vivo // Farmateka. – 2018; 2 (355): 74–8 (in Russ.)]. DOI: https://dx.doi.org/10.18565/pharmateca.2018.2.74-78.
  34. Holz C., Busjahn A., Mehling H. et al. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study // Probiotics Antimicrob. Proteins. – 2015; 7 (2): 91–100. DOI: 10.1007/s12602-014-9181-3.
  35. Mehling H., Busjahn A. Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans // Nutrients. – 2013; 5: 3062–73.
  36. Francavilla R., Polimeno L., Demichina A. et al Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study // J. Clin. Gastroenterol. – 2014; 48 (5): 407–13. DOI: 10.1097/MCG.0000000000000007.
  37. Dore M., Cuccu M., Pes G. et al. Lactobacillus reuteri in the treatment of Helicobacter pylori infection // Intern. Emerg. Med. – 2014; 9 (6): 649–54. DOI: 10.1007/s11739-013-1013-z.
  38. Muresan I., Pop L., Dumitrascu D. Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia // Med. Pharm. Rep. – 2019; 92 (4): 352–5. DOI: 10.15386/mpr-1375.
  39. Bordin D.S., Vojnovan I.N., Homeriki S.G. i dr. Effektivnost' i bezopasnost' probioticheskih bakterij Lactobacillus reuteri DSMZ17648 u infitsirovannyh Helicobacter pylori, ne imejuschih absoljutnyh pokazanij dlja eradikatsionnoj terapii: rezul'taty issledovanija // Lechaschij vrach. – 2016; 5 [Bordin D.S., Voinovan I.N., Khomeriki S.G. et al. Efficiency and safety of Lactobacillus reuteri DSMZ17648 in patients infected with Helicobacter pylori // Lechashchii vrach. – 2016; 5 (in Russ.)]. URL: https://www.lvrach.ru/2016/05/15436483/ (data obraschenija 06.12.2019).
  40. Parolova N.I., Kornienko E.A., Antonov P.V. i dr. Innovatsionnyj podhod v terapii infektsii N. pylori u detej // RMZh. – 2015; 22: 1339–40 [Parolova N.I., Kornienko E.A., Antonov P.V. i dr. Innovatsionnyi podkhod v terapii infektsii H. pylori u detei // RMZh. – 2015; 22: 1339–40 (in Russ.)].
  41. Uspenskij Ju.P., Fominyh Ju.A., Ivanov S.V. i dr. Evoljutsija v eradikatsionnoj terapii NR-assotsiirovannyh zabolevanij. Vyhod za ramki standartov? // RMZh. – 2016; 17: 1144–52 [Uspenskii Yu.P., Fominykh Yu.A., Ivanov S.V. i dr. Evolyutsiya v eradikatsionnoi terapii HP-assotsiirovannykh zabolevanii. Vykhod za ramki standartov? // RMZh. – 2016; 17: 1144–52 (in Russ.)].
  42. Uspenskij Ju.P., Baryshnikova N.V., Fominyh Ju.A. Lechenie infektsii Helicobacter pylori: problemy i perspektivy // Consilium Medicum. Gastroenterologija. (Pril.). – 2015; 1: 8–17 [Uspenskiy Yu.P., Baryshnikova N.V., Fominykh Yu.A. The treatment of Helicobacter pylori: problems and prospects // Consilium Medicum. Gastroenterologiya. (Pril.). – 2015; 1: 8–17 (in Russ.)].
  43. Tkachenko E., Uspenskij Ju., Baryshnikova N. Optimizatsija lechenija zabolevanij, assotsiirovannyh s Helicobacter pylori // Vrach. – 2012; 1: 36–8 [Tkachenko E., Uspenskiy Yu., Baryshnikova N. Optimization of treatment for Helicobacter Pylori-associated diseases // Vrach. – 2012; 1: 36–8 (in Russ.)].